A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Breast Cancer Metastatic

Treatments: Drug: PF-03084014; Drug: Docetaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT01876251

2013-000659-41 (EudraCT Number)

A8641016

Details and patient eligibility

About

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

Enrollment: 30 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.

Exclusion criteria

• Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.

Trial design

30 participants in 1 patient group

PF-03084014 plus docetaxel

Experimental group

Description:

PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m\^2

Treatment:

Drug: PF-03084014

Drug: PF-03084014

Drug: Docetaxel

Drug: Docetaxel

Drug: PF-03084014